Apollomics plans to lay off staff, narrow focus for lung cancer trial
Apollomics is making major cost cuts and leadership changes to stay afloat.
The oncology biotech announced Wednesday morning that co-founder and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
